V-Go is designed to simplify basal-bolus insulin therapy
and helps make blood glucose control possible for adults.
[25.] Umpierrez GE, Smiley D, Jacobs S, et al Randomized study of basal-bolus insulin therapy
in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery).
Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy
. Diabetes Obes Metab.
Glytec's patented eGlycemic Management System (eGMS) will be a focal point of the health system's diabetes service line, offering clinicians a set of tools, technologies and processes proven to achieve full adoption of basal-bolus insulin therapy
, the standard of care and best practice endorsed by the American Diabetes Association and American Association of Clinical Endocrinologists.
Basal-bolus insulin therapy
and glycemic control in adult patients with type 2 diabetes mellitus: A review of the literature.
It will be developed and validated initially for people with diabetes on basal-bolus insulin therapy
, but the underlying approach can be adapted to other chronic diseases.
Restoration of the circadian peak in central nervous system (hypothalamic) dopaminergic neuronal activity may represent a potential therapeutic target to improve glycemic control in T2DM patients requiring high-dose basal-bolus insulin therapy
The subgroup of patients receiving basal-bolus insulin therapy
at baseline and at Week 12 allowed a 'like with like' comparison of changes in insulin dosing to be made.
A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy
(Kuma moto Insulin Degludec Observational study).
Blood glucose values of patients who received bolus-only insulin therapy were compared to glucose values for patients who received basal-bolus insulin therapy
. Efficacy was evaluated based upon control of hyperglycemia, while also comparing rates of hypoglycemia between the two groups.
* The risk of hypoglycemia is a major barrier to initiating basal-bolus insulin therapy
. Hypoglycemia is classified as a blood glucose level of <70 mg/dL, and severe hypoglycemia as <50 mg/dL, regardless of whether the patient develops symptoms.
Switching to basal-bolus insulin therapy
from basal insulin or premix insulin therapy requires a few simple steps.